{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Travere Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"TVTX"},"Address":{"label":"Address","value":"3611 VALLEY CENTRE DRIVE,SUITE 300, SAN DIEGO, California, 92130, United States"},"Phone":{"label":"Phone","value":"+1 888 969-7879"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapies for people living with rare diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often lead to end-stage kidney disease."},"CompanyUrl":{"label":"Company Url","value":"https://www.travere.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Eric M. Dube","title":"President, Chief Executive Officer & Director"},{"name":"Jula Inrig","title":"Chief Medical Officer"},{"name":"William E. Rote","title":"Senior VP, Head-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}